Gaitherburg-based OpGen Inc. has entered a new partnership with pharmaceutical giant Merck & Co. in a collaboration officials say will help more quickly combat so-called superbugs with rapid diagnostic tests.
OpGen, which has focused on creating rapid DNA diagnostic tools to improve antibiotic decision-making, has been building a bank of bacterial pathogens to offer more accurate infection diagnostic testing.
Under the partnership, Merck (NYSE: MRK) intends to provide OpGen access to its archive…
Gaitherburg-based OpGen Inc. has entered a new partnership with pharmaceutical giant Merck & Co. in a collaboration officials say will help more quickly combat so-called superbugs with rapid diagnostic tests.
OpGen, which has focused on creating rapid DNA diagnostic tools to improve antibiotic decision-making, has been building a bank of bacterial pathogens to offer more accurate infection diagnostic testing.
Under the partnership, Merck (NYSE: MRK) intends to provide OpGen access to its archive…